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Other names: CLG4 (Collagenase Type IV); CLG4A 
(Collagenase Type IV-A); TBE-1(as secreted by H-ras 





This gene can be found on chromosome 16 at location: 
54,070,604-54,097,652. 
Transcription 
The DNA sequence contains 13 exons and the 




MMP2 is a Zn+2 dependent endopeptidase, synthesized 
and secreted in zymogen form. The nascent form of the 
protein shows an N-terminal signal sequence ('pre' 
domain) that directs the protein to the endoplasmic 
reticulum. The pre domain is followed by a propeptide-
'pro' domain that maintains enzyme-latency until 
cleaved or disrupted, and a catalytic domain that 






Domain structure of the MMP2. 
Pre: signal sequence; 
Pro: propeptide with a free zinc-ligating thiol (SH) group; 
Zn: zinc-binding site; 
II: collagen-binding fibronectin type II inserts; 
H: hinge region;  
The hemopexin/vitronectin-like domain contains four repeats with the first and last linked by a disulfide bond. 
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A hemopexin/vitronectin-like domain is also seen, that 
is connected to the catalytic domain by a hinge or 
linker region. The hemopexin domain is involved in 
TIMP (Tissue Inhibitors of Metallo-Proteinases) 
binding, the binding of certain substrates, membrane 
activation, and some proteolytic activities. It also 
shows a series of three head-to-tail cysteine-rich 
repeats within its catalytic domain. These inserts 
resemble the collagen-binding type II repeats of 
fibronectin and are required to bind and cleave collagen 
and elastin. 
The regulation of MMP-2 activity occurs at many 
levels, of which regulation through TIMP-2 and its cell 
surface receptor, MT1-MMP (MMP14) is critically 
decisive. At higher levels of TIMP-2, MT1-MMP 
forms a ternary complex with MMP-2 through, leaving 
no free MT1-MMP receptors, thereby inhibiting the 
activation of pro-MMP-2 by MT1-MMP. But at lower 
levels of TIMP-2, due to availability of free MT1-
MMP, MT1-MMP mediated activation of MMP-2 is 
observed. Further data also indicates that expression of 
TIMP-2, MMP-2 and MT1-MMP (MMP-14) is co-
regulated transcriptionally, demonstrating an intricate 
network of regulation. Pro-MMP-2 activation is also 
seen by complex signaling induced by ECM proteins 
like osteopontin, various cytokines for example IL-8 in 
endothelial cells and other factors. 
Expression 





Primary function is degradation of proteins in the 
extracellular matrix. It proteolytically digests gelatin 
(denatured collagen), and types IV, V, VII, IX and X 
collagen. Physiologically, MMP-2 in coordination with 
other MMPs, play a role in normal tissue remodeling 
events such as embryonic development, angiogenesis, 
ovulation, mammary gland involution and wound 
healing. MMP2 is also involved in osteoblastic bone 
formation and/or inhibits osteoclastic bone resorpti n. 
Homology 
Homology in amino acid sequence is seen with the 




A G-to-A transition in codon 101 of exon 2 of MMP2 
gene was detected in a Saudi family with idiopathic 
multicentric osteolysis. This mutation showed a 
replacement of an arginine by histidine (R101H) in the  
prodomain, a region highly conserved across species 
and other members of the MMP gene family that is 
involved in autoproteolytic activation of MMP2. 
In a case of Winchester Syndrome, a homozygous 
1210G-A transition in exon 8 of the MMP2 gene, leads 
to glu-to-lys (E404K) substitution in the catalytic 
domain of the protein. The glutamic acid at codon 404
is believed to be essential for the peptidase activity of 
all metalloproteinases, as its carboxyl group catalyzes 2 
proton transfers, helps stabilize the transition state, and 
triggers the release of the products. 
Implicated in 
Elevated expression of MMP-2, along with MMP-9 is 
usually seen in invasive and highly tumorigenic cancers 
such as colorectal tumors, gastric carcinoma, pancre ti  
carcinoma, breast cancer, oral cancer, melanoma, 
malignant gliomas, Chondrosarcoma, gastrointestinal 
adenocarcinoma. Levels are also increased in malignant 
astrocytomas, carcinomatous meningitis, and brain 
metastases. 
Oncogenesis 
MMPs promote tumor progression and metastasis in 
invasive cancers by degradation of the ECM 
(ExtraCellular Matrix), which consists of two main 
components: Basement membranes and interstitial 
connective tissue. Though ECM comprises of many 
proteins (laminin-5, proteoglycans, entactin, 
osteonectin) collagen IV is the major element. MMP-2 
& MMP-9 efficiently degrade collagen IV and laminin-
5 thereby, assisting the metastatic cancerous cellsto 
pass through the basement membrane. The degradation 
of ECM not only assists migration of metastatic 
cancerous cells, but also allows enhanced tumor growth 
by providing necessary space. Further, it is noteworthy 
that the ratio of active to latent form of MMP-2 
increased with tumor progression in invasive cancers. 
MMP-2, with its family members also promotes 
angiogenesis (a critical process required for tumor cell 
survival) by degrading the vascular basement 
membrane and the interstitium. 
Note: Arthritis, Autosomal recessive osteolysis 
disorder, Coronary Artery disease, pulmonary-
emphysema and diabetic retinopathy. 
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